CAR T-cell therapy is a treatment where a patient's own T-cells (a type of white blood cell) are changed in the lab to attack cancer cells. This study looks at how safe and possible it is to use this treatment in people with kidney problems. The study will use a special kind of chemotherapy called *dose-adjusted lymphodepleting chemotherapy* to prepare patients before giving them CAR T-cell therapy. This is important for people who have kidney issues, like those whose kidneys don't work well, to see if the treatment works for them too.
To join, you must have certain health conditions, like being treated for cancers such as multiple myeloma, leukemia, or lymphoma, and have enough healthy bone marrow to get chemotherapy. Your kidney function should be less than or equal to 60mL/min/1.73m2, which measures how well your kidneys work. You shouldn't join if you have serious brain problems, uncontrolled infections, or are taking high doses of steroids.
- This study is for those with moderate to severe kidney issues receiving CAR T-cell therapy.
- Participants must have specific types of cancer and meet certain health requirements.
- Some health conditions or medications may prevent you from joining.